Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study

Simple item page
dc.contributor.authorGuler O.C.
dc.contributor.authorOymak E.
dc.contributor.authorYazici G.
dc.contributor.authorAkagunduz O.O.
dc.contributor.authorCetinayak O.
dc.contributor.authorErpolat P.
dc.contributor.authorAksoy A.
dc.contributor.authorDuzova M.
dc.contributor.authorYildirim B.A.
dc.contributor.authorKurt M.
dc.contributor.authorCanyilmaz E.
dc.contributor.authorYavas G.
dc.contributor.authorAkyurek S.
dc.contributor.authorOksuz D.C.
dc.contributor.authorSaglam E.K.
dc.contributor.authorCelik O.K.
dc.contributor.authorOzyar E.
dc.contributor.authorCengiz M.
dc.contributor.authorOnal C.
dc.date.accessioned2024-07-22T08:03:37Z
dc.date.available2024-07-22T08:03:37Z
dc.date.issued2023
dc.description.abstractThe aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni-and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients’ performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78–7.00, p < 0.001) and PFS (HR = 4.28, 95% CI, 2.79–6.58, p < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12–2.98, p = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did. © 2023, Tech Science Press. All rights reserved.
dc.identifier.DOI-ID10.32604/or.2023.028840
dc.identifier.issn09650407
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12370
dc.language.isoEnglish
dc.publisherTech Science Press
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCarcinoma
dc.subjectChemoradiotherapy
dc.subjectEsophageal Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectRetrospective Studies
dc.subjectUterine Cervical Neoplasms
dc.subjectcarboplatin
dc.subjectcisplatin
dc.subjectfluorouracil
dc.subjectpaclitaxel
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcancer staging
dc.subjectchemoradiotherapy
dc.subjectcontrolled study
dc.subjectesophagus carcinoma
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectlocal recurrence free survival
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study (topic)
dc.subjectoverall survival
dc.subjectprogression free survival
dc.subjectradiation dose
dc.subjectretrospective study
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjecttumor volume
dc.subjectuterine cervix carcinoma
dc.subjectcarcinoma
dc.subjectchemoradiotherapy
dc.subjectclinical trial
dc.subjectesophagus tumor
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectuterine cervix tumor
dc.subjectvery elderly
dc.titleMulti-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu